NorthRock Partners LLC boosted its stake in Celgene Corporation (NASDAQ:CELG) by 6.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 8,610 shares of the biopharmaceutical company’s stock after buying an additional 525 shares during the quarter. Celgene makes up approximately 0.5% of NorthRock Partners LLC’s portfolio, making the stock its 13th largest holding. NorthRock Partners LLC’s holdings in Celgene were worth $1,118,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Peoples Bank OH lifted its stake in Celgene by 3.1% in the 1st quarter. Peoples Bank OH now owns 4,067 shares of the biopharmaceutical company’s stock worth $506,000 after purchasing an additional 124 shares in the last quarter. Budros Ruhlin & Roe Inc. lifted its stake in Celgene by 6.6% in the 1st quarter. Budros Ruhlin & Roe Inc. now owns 4,050 shares of the biopharmaceutical company’s stock worth $504,000 after purchasing an additional 250 shares in the last quarter. Carret Asset Management LLC lifted its stake in Celgene by 2.9% in the 1st quarter. Carret Asset Management LLC now owns 9,030 shares of the biopharmaceutical company’s stock worth $1,124,000 after purchasing an additional 255 shares in the last quarter. Legacy Capital Partners Inc. lifted its stake in Celgene by 6.8% in the 1st quarter. Legacy Capital Partners Inc. now owns 29,809 shares of the biopharmaceutical company’s stock worth $3,710,000 after purchasing an additional 1,885 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Celgene by 36.8% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 466,622 shares of the biopharmaceutical company’s stock worth $58,061,000 after purchasing an additional 125,428 shares in the last quarter. 79.48% of the stock is currently owned by hedge funds and other institutional investors.

In related news, insider Terrie Curran sold 1,727 shares of Celgene stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Gilla Kaplan sold 9,250 shares of Celgene stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the sale, the director now owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The disclosure for this sale can be found here. Insiders sold a total of 20,227 shares of company stock valued at $2,843,956 in the last quarter. 0.95% of the stock is owned by insiders.

Shares of Celgene Corporation (NASDAQ CELG) opened at $104.50 on Monday. Celgene Corporation has a 1-year low of $94.55 and a 1-year high of $147.17. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $82,274.63, a P/E ratio of 16.33, a P/E/G ratio of 0.81 and a beta of 1.79.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. During the same quarter last year, the firm earned $1.58 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. equities analysts expect that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

A number of research analysts have weighed in on CELG shares. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 target price on the stock. in a research note on Tuesday, August 29th. Royal Bank Of Canada decreased their target price on shares of Celgene from $166.00 to $148.00 and set a “top pick” rating on the stock in a research note on Friday, October 27th. Leerink Swann reissued a “buy” rating and issued a $156.00 target price on shares of Celgene in a research note on Friday, October 20th. Morgan Stanley decreased their target price on shares of Celgene from $120.00 to $115.00 and set an “underweight” rating on the stock in a research note on Monday, October 23rd. Finally, Cantor Fitzgerald reissued a “buy” rating on shares of Celgene in a research note on Monday, August 28th. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average target price of $139.57.

WARNING: This article was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.watchlistnews.com/northrock-partners-llc-raises-position-in-celgene-corporation-celg/1728379.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.